Clinical Study of Effects of Targeting Therapy with Iodine-131 Labeled Monoclonal Antibody for HepatocellularCarcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YAO Quanj un , L U Wusheng

The S econd Department of General S urgery , West China Hos pi tal , S ichuan Uni versi t y , Cheng du 610041 , China;

Corresponding?author：

Keywords：

Iodine-131，Monoclonal antibody ，Targeting therapy ，Hepatocellular carcinoma

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【 Abstract 】 Objective To investigate the clinical effects of targeting therapy with iodine-131 labeled monoclonal antibody for hepatocellular carcinoma (HCC). Methods The related published literatures were reviewed and summarized. Results The reasonable application of targeting therapy with iodine-131 labeled monoclonal antibody could improve the prognosis for patients with HCC especially for some primary HCC. It was used in various kinds of HCC patients with no severe side effects. ConclusionThe targeting therapy with iodine-131 labeled monoclonal antibody may be considered as a safe and effective method to treat HCC and an adjuvant therapy for liver surgery.

Citation： YAO Quanj un,L U Wusheng. Clinical Study of Effects of Targeting Therapy with Iodine-131 Labeled Monoclonal Antibody for HepatocellularCarcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2008, 15(4): 250-253. doi: Copy

1.	Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects [J]. Q J Nucl Med Mol Imaging, 2004; 48(4)∶317.
2.	尚育紅，許莉．單克隆抗體DGDK-1導向治療晚期肝癌臨床研究 [J]. 醫藥論壇雜志， 2004； 25(21)∶13.
3.	Xu J, Xu HY, Zhang Q， et al．Hab18G/CD147 functions in invasion and metastasis of hepatocelluler carcinoma [J]. Mol Cancer Res, 2007; 5(6)∶605.
4.	Bethge WA, Sandmaier BM. Targeted cancer therapy using radiolabeled monoclonal antibodies [J]. Technol Cancer Res Treat, 2005; 4(4)∶393.
5.	Keng GH, Sundram FX. Radionuclide therapy of hepatocellular carcinoma [J]. Ann Acad Med Singapore, 2003; 32(4)∶518.
6.	許成平，王建新，鄭仕中，等．導向內照射化療栓塞治療56例肝癌隨訪報告 [J]. 中華腫瘤雜志， 2000； 22(1)∶42.
7.	李貴平，張輝．腫瘤放射免疫靶向治療研究的現狀與進展 [J]. 放射免疫雜志， 2004； 17(5)∶387.
8.	Kobayashi H, Nakajo M, Shimabukuro K, et al．Possibility of radiotherapy of hepatic cancer by transcatheter arterial embolization with radioactive Lipiodol [J]. Nippon Igaku Hoshasen Gakkai Zasshi, 1984; 44(1)∶96.
9.	Raoul JL, Bourguet P, Bretagne JF, et al．Hepatic artery injection of I-131-labeled lipiodol. Part Ⅰ. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases [J]. Radiology, 1988; 168(2)∶541.
10.	吳少平，盧武勝． 131I標記物介入治療肝癌的臨床研究進展 [J]. 中國普外基礎與臨床雜志， 2003； 10(5)∶513.
11.	Lau WY. Management of hepatocellular carcinoma [J]. J R Coll Surg Edinb, 2002; 47(1)∶389.
12.	Giovannini M, Elias D, Monges G, et al．Hepatocellular carcinoma [J]. Br J Cancer, 2001; 84 Suppl 2∶74.
13.	Raoul JL, Messner M, Boucher E, et al．Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol [J]. Br J Surg, 2003; 90(11)∶1379.
14.	Boucher E, Corbinais S, Rolland Y, et al．Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma [J]. Hepatology, 2003; 38(5)∶1237.
15.	Brans B, Van Laere K, Gemmel F, et al．Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma [J]. Eur J Nucl Med Mol Imaging, 2002; 29(7)∶928.
16.	盧武勝，李肖，王朝華，等． 131I-HAb18F(ab’)2在肝癌患者體內的生物學分布 [J]. 生物醫學工程學雜志， 2003； 20(4)∶689.
17.	蔡紅兵，羅榮城，李愛民． 131I-組合單克隆抗體局部放射免疫導向治療肝癌的臨床觀察 [J]. 解放軍醫學雜志， 2003； 28(10)∶926.
18.	Yang LJ, Sui YF, Chen ZN. Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab’)(2) fragment and staphylococcal enterotoxin A [J]. World J Gastroenterol, 2001; 7(2)∶216.
19.	Risse JH, Grünwald F, Kersjes W, et al．Intraarterial HCC therapy with I-131-Lipiodol [J]. Cancer Biother Radiopharm, 2000; 15(1)∶65.
20.	施常備，袁彬．131碘標記肝癌單抗片段介入治療原發性肝癌的臨床毒副作用觀察 [J]. 現代腫瘤醫學，2004； 12(6)∶549.
21.	馮強. 抗人肝癌單抗片段抗體HAb18F(ab’)2 的凍干工藝研究 [J]. 生物技術通訊， 2002； 13(5)∶356.
22.	李云春，譚天秩，莫廷樹，等．利卡汀的人體顯像和組織分布 [J]. 同位素， 2007； 20(3)∶135.
23.	Chen ZN, Mi L, Xu J, et al．Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase Ⅰ/Ⅱtrials [J]. Int J Radiat Oncol Biol Phys, 2006; 65(2)∶435.
24.	吳少平，盧武勝，徐大偉，等．肝癌DSA血供類型與經肝動脈灌注131I-HAbl8F(ab’)2治療后瘤體大小變化的關系探討 [J]. 介入放射學雜志， 2007； 16(4)∶243.
25.	吳少平，盧武勝，徐大偉，等．經肝動脈灌注131I-HAb18F(ab’)2治療肝癌合并門靜脈癌栓療效分析 [J]. 介入放射學雜志， 2007； 16(8)∶560.
26.	許國輝，張智慧，李政文，等． 131I肝癌單抗片段HAb18F(ab’)2灌注治療原發性肝癌的臨床研究 [J]. 介入放射學雜志，2005； 14(6)∶596.
27.	李云春，譚天秩，莫廷樹，等．碘[131]I-美妥昔單抗注射液的人體藥代動力學研究 [J]. 生物醫學工程學雜志， 2007； 24(4)∶857.
28.	Chen S, Li B, Xie H, et al．Phase Ⅰclinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma [J]. Cancer Biother Radiopharm, 2004; 19(5)∶589.
29.	Zeng ZC, Tang ZY, Yang BH, et al．Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma [J]. Eur J Nucl Med Mol Imaging, 2002; 29(12)∶1657.
30.	楊儀，劉增禮，唐軍，等． 131I標記抗人肝癌單克隆抗體人體內照射劑量計算 [J]. 蘇州大學學報（醫學版）， 2007； 27(1)∶114.
31.	項明，朱上林，林言箴，等． 131I-Hepama-1單克隆抗體導向治療肝癌的初步觀察 [J]. 中國腫瘤臨床， 1998； 25(4)∶289.
32.	金堅，張滿達，王博誠，等．人心肌酸性鐵蛋白與肝癌關系的研究 [J]. 中國核科技報告， 1997； 00∶933.
33.	范楨，湯釗猷，袁愛娜，等．抗人肝癌鐵蛋白抗體對原發性肝癌患者的放射免疫顯像 [J]. 上海醫科大學學報， 1990； 17(6)∶405.
34.	Fan Z, Tang Z, Liu K, et al．Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion [J]. J Cancer Res Clin Oncol, 1992; 118(5)∶371.
35.	畢向軍．抗體在肝癌臨床和研究中的應用及展望 [J]. 國際醫藥衛生報, 2002； 2(3)∶46.
36.	吳英德，楊克政，劉由庚，等． 131I-抗AFP抗體導向治療肝癌的臨床觀察 [J]. 腫瘤， 1994； 14(4)∶200.
37.	Ekberg H, Tranberg KG, Andersson R, et al．Pattern of recurrence in liver resection for colorectal secondaries [J]. World J Surg, 1987; 11(4)∶541.
38.	GE HY， Zuo GH．Inhibiting effects of 131I-labeled anti-CEA monoclonal antibodies injected intrasplenically on liver metastasis from human colonic adenocarcinoma [J]. J Med Coll PLA， 2003； 18(6)∶355.
39.	葛海燕，左國華，高明發． 131I標記抗CEA單抗預防人結腸癌肝轉移的實驗研究 [J]. 第三軍醫大學學報， 2000； 22(5)∶430.
40.	Kinuya S, Yokoyama K, Koshida K, et al．Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy [J]. Eur J Nucl Med Mol Imaging, 2004; 31(7)∶981.
41.	Ychou M, Pelegrin A, Faurous P, et al．Phase-radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab’)2 in patients with non-resectable liver metastases from colorectal cancer [J]. Int J Cancer, 1998; 75(4)∶615.
42.	羅時敏，張天順．原發性肝癌的免疫治療 [J]. 肝膽外科雜志， 2000； 8(6)∶463.
43.	劉曉波，蔡美英．載131I和阿霉素“雙彈頭”免疫毫微粒的抗癌作用 [J]. 中華實驗外科雜志， 2003； 20(2)∶188.
44.	劉曉波，蔡美英，闞和平，等．載131I和阿霉素“雙彈頭” F(ab’)2片段免疫毫微粒的抗人肝癌作用 [J]. 實用癌癥雜志， 2007； 22(1)∶1.
45.	李凱，封國生．肝臟惡性腫瘤的放射性粒子植入治療 [J]. 實用醫學雜志， 2005； 21(17)∶1977.
46.	Bacher K, Brans B, Monsieurs M, et al ． Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? [ J ] . Eur J Nucl Med Mol Imaging, 2002; 29(10) ∶ 1311.

1. 　Van de Wiele C, Revets H, Mertens N. Radioimmunoimaging. Advances and prospects [J]. Q J Nucl Med Mol Imaging, 2004; 48(4)∶317.
2. 　尚育紅，許莉．單克隆抗體DGDK-1導向治療晚期肝癌臨床研究 [J]. 醫藥論壇雜志， 2004； 25(21)∶13.
3. 　Xu J, Xu HY, Zhang Q， et al．Hab18G/CD147 functions in invasion and metastasis of hepatocelluler carcinoma [J]. Mol Cancer Res, 2007; 5(6)∶605.
4. 　Bethge WA, Sandmaier BM. Targeted cancer therapy using radiolabeled monoclonal antibodies [J]. Technol Cancer Res Treat, 2005; 4(4)∶393.
5. 　Keng GH, Sundram FX. Radionuclide therapy of hepatocellular carcinoma [J]. Ann Acad Med Singapore, 2003; 32(4)∶518.
6. 　許成平，王建新，鄭仕中，等．導向內照射化療栓塞治療56例肝癌隨訪報告 [J]. 中華腫瘤雜志， 2000； 22(1)∶42.
7. 　李貴平，張輝．腫瘤放射免疫靶向治療研究的現狀與進展 [J]. 放射免疫雜志， 2004； 17(5)∶387.
8. 　Kobayashi H, Nakajo M, Shimabukuro K, et al．Possibility of radiotherapy of hepatic cancer by transcatheter arterial embolization with radioactive Lipiodol [J]. Nippon Igaku Hoshasen Gakkai Zasshi, 1984; 44(1)∶96.
9. 　Raoul JL, Bourguet P, Bretagne JF, et al．Hepatic artery injection of I-131-labeled lipiodol. Part Ⅰ. Biodistribution study results in patients with hepatocellular carcinoma and liver metastases [J]. Radiology, 1988; 168(2)∶541.
10. 　吳少平，盧武勝． 131I標記物介入治療肝癌的臨床研究進展 [J]. 中國普外基礎與臨床雜志， 2003； 10(5)∶513.
11. 　Lau WY. Management of hepatocellular carcinoma [J]. J R Coll Surg Edinb, 2002; 47(1)∶389.
12. 　Giovannini M, Elias D, Monges G, et al．Hepatocellular carcinoma [J]. Br J Cancer, 2001; 84 Suppl 2∶74.
13. 　Raoul JL, Messner M, Boucher E, et al．Preoperative treatment of hepatocellular carcinoma with intra-arterial injection of 131I-labelled lipiodol [J]. Br J Surg, 2003; 90(11)∶1379.
14. 　Boucher E, Corbinais S, Rolland Y, et al．Adjuvant intra-arterial injection of iodine-131-labeled lipiodol after resection of hepatocellular carcinoma [J]. Hepatology, 2003; 38(5)∶1237.
15. 　Brans B, Van Laere K, Gemmel F, et al．Combining iodine-131 Lipiodol therapy with low-dose cisplatin as a radiosensitiser: preliminary results in hepatocellular carcinoma [J]. Eur J Nucl Med Mol Imaging, 2002; 29(7)∶928.
16. 　盧武勝，李肖，王朝華，等． 131I-HAb18F(ab’)2在肝癌患者體內的生物學分布 [J]. 生物醫學工程學雜志， 2003； 20(4)∶689.
17. 　蔡紅兵，羅榮城，李愛民． 131I-組合單克隆抗體局部放射免疫導向治療肝癌的臨床觀察 [J]. 解放軍醫學雜志， 2003； 28(10)∶926.
18. 　Yang LJ, Sui YF, Chen ZN. Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab’)(2) fragment and staphylococcal enterotoxin A [J]. World J Gastroenterol, 2001; 7(2)∶216.
19. 　Risse JH, Grünwald F, Kersjes W, et al．Intraarterial HCC therapy with I-131-Lipiodol [J]. Cancer Biother Radiopharm, 2000; 15(1)∶65.
20. 　施常備，袁彬．131碘標記肝癌單抗片段介入治療原發性肝癌的臨床毒副作用觀察 [J]. 現代腫瘤醫學，2004； 12(6)∶549.
21. 　馮強. 抗人肝癌單抗片段抗體HAb18F(ab’)2 的凍干工藝研究 [J]. 生物技術通訊， 2002； 13(5)∶356.
22. 　李云春，譚天秩，莫廷樹，等．利卡汀的人體顯像和組織分布 [J]. 同位素， 2007； 20(3)∶135.
23. 　Chen ZN, Mi L, Xu J, et al．Targeting radioimmunotherapy of hepatocellular carcinoma with iodine (131I) metuximab injection: clinical phase Ⅰ/Ⅱtrials [J]. Int J Radiat Oncol Biol Phys, 2006; 65(2)∶435.
24. 　吳少平，盧武勝，徐大偉，等．肝癌DSA血供類型與經肝動脈灌注131I-HAbl8F(ab’)2治療后瘤體大小變化的關系探討 [J]. 介入放射學雜志， 2007； 16(4)∶243.
25. 　吳少平，盧武勝，徐大偉，等．經肝動脈灌注131I-HAb18F(ab’)2治療肝癌合并門靜脈癌栓療效分析 [J]. 介入放射學雜志， 2007； 16(8)∶560.
26. 　許國輝，張智慧，李政文，等． 131I肝癌單抗片段HAb18F(ab’)2灌注治療原發性肝癌的臨床研究 [J]. 介入放射學雜志，2005； 14(6)∶596.
27. 　李云春，譚天秩，莫廷樹，等．碘[131]I-美妥昔單抗注射液的人體藥代動力學研究 [J]. 生物醫學工程學雜志， 2007； 24(4)∶857.
28. 　Chen S, Li B, Xie H, et al．Phase Ⅰclinical trial of targeted therapy using 131I-Hepama-1 mAb in patients with hepatocellular carcinoma [J]. Cancer Biother Radiopharm, 2004; 19(5)∶589.
29. 　Zeng ZC, Tang ZY, Yang BH, et al．Comparison between radioimmunotherapy and external beam radiation therapy for patients with hepatocellular carcinoma [J]. Eur J Nucl Med Mol Imaging, 2002; 29(12)∶1657.
30. 　楊儀，劉增禮，唐軍，等． 131I標記抗人肝癌單克隆抗體人體內照射劑量計算 [J]. 蘇州大學學報（醫學版）， 2007； 27(1)∶114.
31. 　項明，朱上林，林言箴，等． 131I-Hepama-1單克隆抗體導向治療肝癌的初步觀察 [J]. 中國腫瘤臨床， 1998； 25(4)∶289.
32. 　金堅，張滿達，王博誠，等．人心肌酸性鐵蛋白與肝癌關系的研究 [J]. 中國核科技報告， 1997； 00∶933.
33. 　范楨，湯釗猷，袁愛娜，等．抗人肝癌鐵蛋白抗體對原發性肝癌患者的放射免疫顯像 [J]. 上海醫科大學學報， 1990； 17(6)∶405.
34. 　Fan Z, Tang Z, Liu K, et al．Radioiodinated anti-hepatocellular carcinoma (HCC) ferritin. Targeting therapy, tumor imaging and anti-antibody response in HCC patients with hepatic arterial infusion [J]. J Cancer Res Clin Oncol, 1992; 118(5)∶371.
35. 　畢向軍．抗體在肝癌臨床和研究中的應用及展望 [J]. 國際醫藥衛生報, 2002； 2(3)∶46.
36. 　吳英德，楊克政，劉由庚，等． 131I-抗AFP抗體導向治療肝癌的臨床觀察 [J]. 腫瘤， 1994； 14(4)∶200.
37. 　Ekberg H, Tranberg KG, Andersson R, et al．Pattern of recurrence in liver resection for colorectal secondaries [J]. World J Surg, 1987; 11(4)∶541.
38. 　GE HY， Zuo GH．Inhibiting effects of 131I-labeled anti-CEA monoclonal antibodies injected intrasplenically on liver metastasis from human colonic adenocarcinoma [J]. J Med Coll PLA， 2003； 18(6)∶355.
39. 　葛海燕，左國華，高明發． 131I標記抗CEA單抗預防人結腸癌肝轉移的實驗研究 [J]. 第三軍醫大學學報， 2000； 22(5)∶430.
40. 　Kinuya S, Yokoyama K, Koshida K, et al．Improved survival of mice bearing liver metastases of colon cancer cells treated with a combination of radioimmunotherapy and antiangiogenic therapy [J]. Eur J Nucl Med Mol Imaging, 2004; 31(7)∶981.
41. 　Ychou M, Pelegrin A, Faurous P, et al．Phase-radio-immunotherapy study with Iodine-131-labeled anti-CEA monoclonal antibody F6 F(ab’)2 in patients with non-resectable liver metastases from colorectal cancer [J]. Int J Cancer, 1998; 75(4)∶615.
42. 　羅時敏，張天順．原發性肝癌的免疫治療 [J]. 肝膽外科雜志， 2000； 8(6)∶463.
43. 　劉曉波，蔡美英．載131I和阿霉素“雙彈頭”免疫毫微粒的抗癌作用 [J]. 中華實驗外科雜志， 2003； 20(2)∶188.
44. 　劉曉波，蔡美英，闞和平，等．載131I和阿霉素“雙彈頭” F(ab’)2片段免疫毫微粒的抗人肝癌作用 [J]. 實用癌癥雜志， 2007； 22(1)∶1.
45. 　李凱，封國生．肝臟惡性腫瘤的放射性粒子植入治療 [J]. 實用醫學雜志， 2005； 21(17)∶1977.
46. 　 Bacher K, Brans B, Monsieurs M, et al ． Thyroid uptake and radiation dose after (131)I-lipiodol treatment: is thyroid blocking by potassium iodide necessary? [ J ] . Eur J Nucl Med Mol Imaging, 2002; 29(10) ∶ 1311.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Clinical Study of Effects of Targeting Therapy with Iodine-131 Labeled Monoclonal Antibody for HepatocellularCarcinoma

Abstract Full text Figures/Tables Video References Cited by

Format

Content